SOURCE: StockCall

StockCall

August 22, 2011 08:51 ET

Research on AstraZeneca plc and Abbott Laboratories - Restructuring Efforts Help but New Drugs Still Key for Big Pharma

JOHANNESBURG, SOUTH AFRICA--(Marketwire - Aug 22, 2011) - www.stockcall.com/ offers investors comprehensive research on the Drug Manufacturers - Major industry and has completed analytical research on AstraZeneca plc (NYSE: AZN) and Abbott Laboratories (NYSE: ABT). Register with us today at www.stockcall.com/ to have free access to these researches.

Expiring patents and generic competition continue to threaten revenues for major drug manufacturers. Restructuring efforts are helping some companies cut costs, but getting new drugs to the market is still a top priority for most drug makers. Register now at https://stockcall.com/development/stockcall/page.php?name=register.html to have free access to our reports on the Drug Manufacturers - Major industry.

www.stockcall.com/ is an online platform where investors doing their due-diligence on the Drug Manufacturers - Major industry can have easy and free access to our analyst research and opinions on AstraZeneca plc and Abbott Laboratories; investors and shareholders of these companies can simply register for a complimentary membership at https://stockcall.com/development/stockcall/page.php?name=register.html.

AstraZeneca plc could offset patent expiration losses with its restructuring program. The second phase of its restructuring program began in January 2010, but aims to trim $1.9 billion, half of which is to be seen in 2011, by the end of 2014. Investors can register for free to access the research report on AstraZeneca plc at www.stockcall.com/AZN220811.pdf.

Restructuring efforts will positively affect margins in the short-term. Nonetheless, maintaining a steady pipeline of drugs to the market is paramount for long-term gains. Recently published trial updates were favorable for a few industry leaders. Abbott Laboratories reported positive results from a Phase 2b trial of a compound for patients with relapsing multiple sclerosis. Getting the compound through trials could positively impact revenues for the drug maker considering the scope of annual multiple sclerosis spending. Investors can register for free to access the research report on Abbott Laboratories at www.stockcall.com/ABT220811.pdf.

Moving forward, cost-cutting efforts will certainly help, however, investors may want to focus more on companies posting encouraging trial results and positively interacting with patent expirations. Visit www.stockcall.com/ to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

About StockCall.com
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information